The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. This research explores using less extensive surgery for cervical cancer and using targeted therapy to reduce the risk of breast cancer recurrence.
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery.
Read research from the March 2023 session of the ASCO Plenary Series, which highlights a study evaluating a new targeted therapy drug given in combination with chemotherapy for people with advanced gastric or gastroesophageal junction cancer.
Read about two studies presented at the 2023 Genitourinary Cancers Symposium, covering plant-based diets and prostate cancer and a promising combination treatment for metastatic castration-resistant prostate cancer.
Read research from the February 2023 session of the ASCO Plenary Series, which highlights a study comparing 2 targeted therapy drugs for treating people with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
In this podcast, Dr. Christopher Flowers discusses new research from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, including new treatments for non-Hodgkin lymphoma and models for predicting early disease progression.
Read research from the January 2023 session of the ASCO Plenary Series, which highlights a study evaluating a blood-based test to select treatment for advanced gastrointestinal stromal tumors (GISTs).
